Further analysis found that the methylation level of IL21R showed a more excellent ability to discriminate early-stage BC patients from patients with benign breast tumours (benign vs. stage 0 & I BC, AUC = 0.90, 95% CI: 0.87–0.93, Figure 4b). This evidence concerns the gene IL21R and breast benign neoplasm.